Barriers to Adoption of Tailored Drug-Drug Interaction Clinical Decision Support

被引:2
|
作者
Zhang, Tianyi [1 ,8 ]
Gephart, Sheila M. [2 ]
Subbian, Vignesh [1 ]
Boyce, Richard D. [3 ]
Villa-Zapata, Lorenzo [4 ]
Tan, Malinda S. [5 ]
Horn, John [6 ]
Gomez-Lumbreras, Ainhoa [5 ]
Romero, Andrew V. [7 ]
Malone, Daniel C. [5 ]
机构
[1] Univ Arizona, Coll Engn, Dept Syst & Ind Engn, Tucson, AZ USA
[2] Univ Arizona, Coll Nursing, Adv Nursing Practice & Sci Div, Tucson, AZ USA
[3] Univ Pittsburgh, Sch Med, Dept Biomed Informat, Pittsburgh, PA USA
[4] Univ Georgia, Coll Pharm, Clin & Adm Pharm, Athens, GA USA
[5] Univ Utah, Coll Pharm, Dept Pharmacotherapy, Salt Lake City, UT USA
[6] Univ Washington, Sch Pharm, Dept Pharm, Seattle, WA USA
[7] Tucson Med Ctr, Dept Pharm, Tucson, AZ USA
[8] Univ Arizona, Coll Engn, Dept Syst & Ind Engn, Tucson, AZ 85721 USA
来源
APPLIED CLINICAL INFORMATICS | 2023年 / 14卷 / 04期
基金
美国医疗保健研究与质量局; 美国国家科学基金会;
关键词
drug-drug interaction; clinical decision support systems; electronic health records; implementation science; INTERACTION ALERTS; ORDER-ENTRY; RECOMMENDATIONS; MEDICATION; SYSTEMS;
D O I
10.1055/s-0043-1772686
中图分类号
R-058 [];
学科分类号
摘要
Objective Despite the benefits of the tailored drug-drug interaction (DDI) alerts and the broad dissemination strategy, the uptake of our tailored DDI alert algorithms that are enhanced with patient-specific and context-specific factors has been limited. The goal of the study was to examine barriers and health care system dynamics related to implementing tailored DDI alerts and identify the factors that would drive optimization and improvement of DDI alerts.Methods We employed a qualitative research approach, conducting interviews with a participant interview guide framed based on Proctor's taxonomy of implementation outcomes and informed by the Theoretical Domains Framework. Participants included pharmacists with informatics roles within hospitals, chief medical informatics officers, and associate medical informatics directors/officers. Our data analysis was informed by the technique used in grounded theory analysis, and the reporting of open coding results was based on a modified version of the Safety-Related Electronic Health Record Research Reporting Framework.Results Our analysis generated 15 barriers, and we mapped the interconnections of these barriers, which clustered around three entities (i.e., users, organizations, and technical stakeholders). Our findings revealed that misaligned interests regarding DDI alert performance and misaligned expectations regarding DDI alert optimizations among these entities within health care organizations could result in system inertia in implementing tailored DDI alerts.Conclusion Health care organizations primarily determine the implementation and optimization of DDI alerts, and it is essential to identify and demonstrate value metrics that health care organizations prioritize to enable tailored DDI alert implementation. This could be achieved via a multifaceted approach, such as partnering with health care organizations that have the capacity to adopt tailored DDI alerts and identifying specialists who know users' needs, liaise with organizations and vendors, and facilitate technical stakeholders' work. In the future, researchers can adopt the systematic approach to study tailored DDI implementation problems from other system perspectives (e.g., the vendors' system).
引用
收藏
页码:779 / 788
页数:10
相关论文
共 50 条
  • [1] Management of Drug-Drug Interaction Alerts for Clinical Decision Support in Outpatients
    Su, Chien Hao
    Hsu, Chien Ning
    Tsai, Shu Chen
    Wang, Yu Chin Lily
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2014, 23 : 299 - 299
  • [2] Recommendations to improve the usability of drug-drug interaction clinical decision support alerts
    Payne, Thomas H.
    Hines, Lisa E.
    Chan, Raymond C.
    Hartman, Seth
    Kapusnik-Uner, Joan
    Russ, Alissa L.
    Chaffee, Bruce W.
    Hartman, Christian
    Tamis, Victoria
    Galbreth, Brian
    Glassman, Peter A.
    Phansalkar, Shobha
    van der Sijs, Heleen
    Gephart, Sheila M.
    Mann, Gordon
    Strasberg, Howard R.
    Grizzle, Amy J.
    Brown, Mary
    Kuperman, Gilad J.
    Steiner, Chris
    Sullins, Amanda
    Ryan, Hugh
    Wittie, Michael A.
    Malone, Daniel C.
    [J]. JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION, 2015, 22 (06) : 1243 - 1250
  • [3] SFINX—a drug-drug interaction database designed for clinical decision support systems
    Ylva Böttiger
    Kari Laine
    Marine L. Andersson
    Tuomas Korhonen
    Björn Molin
    Marie-Louise Ovesjö
    Tuire Tirkkonen
    Anders Rane
    Lars L. Gustafsson
    Birgit Eiermann
    [J]. European Journal of Clinical Pharmacology, 2009, 65 : 627 - 633
  • [4] Customizing clinical decision support to prevent excessive drug-drug interaction alerts
    Horn, John R.
    Hansten, Philip D.
    Osborn, Jacqueline D.
    Wareham, Pamela
    Somani, Shabir
    [J]. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2011, 68 (08) : 662 - 664
  • [5] SFINX-a drug-drug interaction database designed for clinical decision support systems
    Bottiger, Ylva
    Laine, Kari
    Andersson, Marine L.
    Korhonen, Tuomas
    Molin, Bjorn
    Ovesjo, Marie-Louise
    Tirkkonen, Tuire
    Rane, Anders
    Gustafsson, Lars L.
    Eiermann, Birgit
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2009, 65 (06) : 627 - 633
  • [6] Drug-drug interaction checking assisted by clinical decision support: a return on investment analysis
    Helmons, Pieter J.
    Suijkerbuijk, Bas O.
    Panday, Prashant V. Nannan
    Kosterink, Jos G. W.
    [J]. JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION, 2015, 22 (04) : 764 - 772
  • [7] Consensus Recommendations for Systematic Evaluation of Drug-Drug Interaction Evidence for Clinical Decision Support
    Scheife, Richard T.
    Hines, Lisa E.
    Boyce, Richard D.
    Chung, Sophie P.
    Momper, Jeremiah D.
    Sommer, Christine D.
    Abernethy, Darrell R.
    Horn, John R.
    Sklar, Stephen J.
    Wong, Samantha K.
    Jones, Gretchen
    Brown, Mary L.
    Grizzle, Amy J.
    Comes, Susan
    Wilkins, Tricia Lee
    Borst, Clarissa
    Wittie, Michael A.
    Malone, Daniel C.
    [J]. DRUG SAFETY, 2015, 38 (02) : 197 - 206
  • [8] Recommendations for selecting drug-drug interactions for clinical decision support
    Tilson, Hugh
    Hines, Lisa E.
    McEvoy, Gerald
    Weinstein, David M.
    Hansten, Philip D.
    Matuszewski, Karl
    le Comte, Marianne
    Higby-Baker, Stefanie
    Hanlon, Joseph T.
    Pezzullo, Lynn
    Vieson, Kathleen
    Helwig, Amy L.
    Huang, Shiew-Mei
    Perre, Anthony
    Bates, David W.
    Poikonen, John
    Wittie, Michael A.
    Grizzle, Amy J.
    Brown, Mary
    Malone, Daniel C.
    [J]. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2016, 73 (08) : 576 - 585
  • [9] Evaluating a Clinical Decision Support System for Drug-Drug Interactions
    Jalali, Amin
    Johannesson, Paul
    Perjons, Erik
    Askfors, Ylva
    Kalladj, Abdolazim Rezaei
    Shemeikka, Tero
    Veg, Aniko
    [J]. MEDINFO 2019: HEALTH AND WELLBEING E-NETWORKS FOR ALL, 2019, 264 : 1500 - 1501
  • [10] Clinical decision support for drug-drug interactions: Improvement needed
    Horn, John R.
    Gumpper, Karl F.
    Hardy, J. Chad
    McDonnell, Patrick J.
    Phansalkar, Shobha
    Reilly, Cynthia
    [J]. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2013, 70 (10) : 905 - 909